WA
IONS icon

Winfield Associates’s Ionis Pharmaceuticals IONS Stock Holding History

Winfield Associates’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,010
Closed -$52K – 366
2017
Q4 		$52K Hold
1,010
– – 0.03% 200
2017
Q3 		$52K Hold
1,010
– – 0.03% 196
2017
Q2 		$52K Hold
1,010
– – 0.03% 193
2017
Q1 		$40K Sell
1,010
-10
-1% -$449 0.02% 199
2016
Q4 		$49K Buy
1,020
+20
+2% +$791 0.03% 182
2016
Q3 		$37K Hold
1,000
– – 0.02% 196
2016
Q2 		$23K Sell
1,000
-60
-6% -$1.94K 0.02% 239
2016
Q1 		$43K Buy
1,060
+60
+6% +$2.44K 0.03% 184
2015
Q4 		$62K Hold
1,000
– – 0.04% 147
2015
Q3 		$40K Buy
+1,000
New +$51.8K 0.03% 168

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Winfield Associates's IONS Position: Q1 2018 in Review

Winfield Associates sold out of Ionis Pharmaceuticals (IONS) in Q1 2018, closing a stake of 1,010 shares — an estimated $52K sold.

Winfield Associates first reported a position in IONS in Q3 2015 and held it in 10 quarters. The position peaked at $62K in Q4 2015. 325 funds tracked by Wall St. Rank hold IONS as of Q1 2018.

  • Winfield Associates reported no remaining Ionis Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 1,010 Ionis Pharmaceuticals shares in Q1 2018, an estimated $52K.
  • Winfield Associates first reported a position in Ionis Pharmaceuticals in Q3 2015 and held it in 10 quarters.
  • Winfield Associates's Ionis Pharmaceuticals position peaked at $62K in Q4 2015.
  • 325 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.